[{"address1": "900 North Point Parkway", "address2": "Suite 200", "city": "Alpharetta", "state": "GA", "zip": "30005", "country": "United States", "phone": "678 270 3631", "fax": "678 270 4033", "website": "https://clearsidebio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.", "fullTimeEmployees": 30, "companyOfficers": [{"maxAge": 1, "name": "Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.", "age": 71, "title": "President, CEO & Director", "yearBorn": 1952, "fiscalYear": 2023, "totalPay": 836154, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles A. Deignan", "age": 59, "title": "Chief Financial Officer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 568676, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Thomas A. Ciulla M.B.A., M.D.", "age": 58, "title": "Chairman of Scientific Advisory Board", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 531517, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jenny R. Kobin", "age": 56, "title": "Head of Investor Relations", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rick  McElheny", "title": "Senior Vice President of Corporate Development & Alliance Management", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rafael V. Andino", "age": 58, "title": "Senior Vice President of Engineering & Manufacturing", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Susan L. Coultas Ph.D.", "title": "Chief Clinical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ngai Hang  Chong FRCOphth, FRCS, M.B.A., M.D.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Leslie B. Zacks", "age": 54, "title": "Secretary", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.06, "open": 1.05, "dayLow": 1.02, "dayHigh": 1.09, "regularMarketPreviousClose": 1.06, "regularMarketOpen": 1.05, "regularMarketDayLow": 1.02, "regularMarketDayHigh": 1.09, "beta": 2.438, "forwardPE": -1.7868853, "volume": 67524, "regularMarketVolume": 67524, "averageVolume": 183853, "averageVolume10days": 214060, "averageDailyVolume10Day": 214060, "bid": 1.05, "ask": 1.13, "bidSize": 100, "askSize": 100, "marketCap": 81456904, "fiftyTwoWeekLow": 0.65, "fiftyTwoWeekHigh": 2.12, "priceToSalesTrailing12Months": 9.637589, "fiftyDayAverage": 1.1947, "twoHundredDayAverage": 1.245015, "currency": "USD", "enterpriseValue": 91431944, "floatShares": 65173026, "sharesOutstanding": 74731104, "sharesShort": 117013, "sharesShortPriorMonth": 193046, "sharesShortPreviousMonthDate": 1718323200, "dateShortInterest": 1721001600, "sharesPercentSharesOut": 0.0016, "heldPercentInsiders": 0.074260004, "heldPercentInstitutions": 0.28636998, "shortRatio": 0.62, "shortPercentOfFloat": 0.0017, "impliedSharesOutstanding": 74731104, "bookValue": -0.292, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -34968000, "trailingEps": -0.55, "forwardEps": -0.61, "enterpriseToRevenue": 10.818, "enterpriseToEbitda": -3.604, "52WeekChange": 0.028301835, "SandP52WeekChange": 0.19031036, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "CLSD", "underlyingSymbol": "CLSD", "shortName": "Clearside Biomedical, Inc.", "longName": "Clearside Biomedical, Inc.", "firstTradeDateEpochUtc": 1464874200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ea57bdfa-5d41-3e30-b431-13e72798980d", "messageBoardId": "finmb_145617165", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.09, "targetHighPrice": 8.0, "targetLowPrice": 4.0, "targetMeanPrice": 5.5, "targetMedianPrice": 5.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 35355000, "totalCashPerShare": 0.473, "ebitda": -25368000, "totalDebt": 45330000, "quickRatio": 5.942, "currentRatio": 6.07, "totalRevenue": 8452000, "revenuePerShare": 0.132, "returnOnAssets": -0.37495, "freeCashflow": -17975500, "operatingCashflow": -18770000, "revenueGrowth": 56.5, "grossMargins": 0.958, "operatingMargins": -35.6913, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-10"}]